Variant TREM2 Signaling in Alzheimer's Disease.

Autor: Olufunmilayo EO; Laboratory of Molecular Neuroscience and Dementia, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW 2050 Australia; University College Hospital, Ibadan, Oyo State, Nigeria. Electronic address: https://twitter.com/@eddietobie., Holsinger RMD; Laboratory of Molecular Neuroscience and Dementia, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW 2050 Australia; Neuroscience, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW 2006 Australia. Electronic address: damian.holsinger@sydney.edu.au.
Jazyk: angličtina
Zdroj: Journal of molecular biology [J Mol Biol] 2022 Apr 15; Vol. 434 (7), pp. 167470. Date of Electronic Publication: 2022 Feb 01.
DOI: 10.1016/j.jmb.2022.167470
Abstrakt: Alzheimer's disease is the most common form of dementia, accounting for as much as three-quarters of cases globally with individuals in low- and middle-income countries being worst affected. Numerous risk factors for the disease have been identified and our understanding of gene-environment interactions have shed light on several gene variants that contribute to the most common, sporadic form of Alzheimer's disease. Triggering Receptor Expressed on Myeloid cells 2 (TREM2) is an important receptor that is crucial to the functioning of microglial cells, and variants of this protein have been found to be associated with a significantly increased risk of Alzheimer's disease. Several studies have elucidated the signaling processes involved in the normal functioning of the TREM2 receptor. However, current knowledge of the idiosyncrasies of the signaling processes triggered by stimulation of the variants of this receptor is limited. In this review, we examine the existing literature and highlight the effects that various receptor variants have on downstream signaling processes and discuss how these perturbations may affect physiologic processes in Alzheimer's disease. Despite the fact that this is a territory yet to be fully explored, the studies that currently exist report mostly quantitative effects on signaling. More mechanistic studies with the aim of providing qualitative results in terms of downstream signaling among these receptor variants are warranted. Such studies will provide better opportunities of identifying therapeutic targets that may be exploited in designing new drugs for the management of Alzheimer's disease.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: